scholarly journals Psoriasin: A Novel Marker Linked Obesity with Psoriasis

2013 ◽  
Vol 34 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Ragaa H. M. Salama ◽  
Hani A. Al-Shobaili ◽  
Ahmad A. Al Robaee ◽  
Abdullateef A. Alzolibani
Keyword(s):  
Psoriatic Arthritis ◽  
Plaque Psoriasis ◽  
Healthy Subjects ◽  
Severity Index ◽  
The Other ◽  
Chronic Plaque Psoriasis ◽  
Psoriasis Area Severity Index ◽  
Age And Sex

To evaluate the role of psoriasin, koebnerisin, interleukn (IL)-12 and IL-23 in the pathogenesis of psoriasis and their relations to Psoriasis Area Severity Index (PASI) and obesity. Thirty patients had chronic plaque psoriasis and 30 healthy subjects matched in age and sex were enrolled in this study. Serum from all subjects were used for determination of psoriasin, koebnerisin, IL-12 and IL-23 by ELISA kits. IL-23 and psoriasin were significantly higher in skin psoriasis compared to controls and psoriatic arthritis (PsA). There was a correlation between psoriasin and both PASI and obesity. On the other hand, IL-12 was significantly increased in PsA compared to skin psoriasis (p= 0.000) and controls. Its sensitivity and specificity were 87%, 93%; respectively. To our knowledge, psoriasin is the first biomarker confirm the link between obesity and psoriasis. The risk of developing psoriasis is directly related to higher BMI.

scholarly journals Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
K. M. Darch ◽  
T. L. Holland ◽  
L. J. Spelman
Keyword(s):  
Inflammatory Bowel Disease ◽  
Psoriatic Arthritis ◽  
Plaque Psoriasis ◽  
Bowel Disease ◽  
Human Monoclonal Antibody ◽  
Biologic Agents ◽  
Chronic Plaque Psoriasis ◽  
Inflammatory Conditions ◽  
Inflammatory Bowel

Chronic plaque psoriasis and psoriatic arthritis are common autoimmune inflammatory conditions, often existing as comorbidities that have a significant impact on a patient’s quality of life. The availability of a range of novel, targeted therapies for their treatment, most notably the availability of biologic agents, has revolutionised management of these conditions and allowed for significant improvements in patient outcomes. Secukinumab (Cosentyx), a fully-human monoclonal antibody that acts by selectively binding to and neutralising the proinflammatory cytokine IL-17A, is used widely for the treatment of both chronic plaque psoriasis and psoriatic arthritis. In this report, we discuss the case of a 54-year-old female with chronic plaque psoriasis and psoriatic arthritis, who experienced the onset of symptoms and was subsequently diagnosed with Crohn’s disease during treatment with secukinumab. It was determined by the gastroenterologist that this may represent secukinumab-induced inflammatory bowel disease. We will review the current understanding of the role of IL-17 in inflammatory bowel disease and the important role of novel agents that target the p19 subunit of IL-23 which have shown significant promise in the management of not only chronic plaque psoriasis and psoriatic arthritis, but also inflammatory bowel disease itself.

scholarly journals The Interaction between the Sheet/Tool Surface Texture and the Friction/Galling Behaviour on Aluminium Deep Drawing Operations

Metals ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 979
Author(s):  
Alaitz Zabala ◽  
Lander Galdos ◽  
Chris Childs ◽  
Iñigo Llavori ◽  
Andrea Aginagalde ◽  
...  
Keyword(s):  
Lightweight Design ◽  
Severity Index ◽  
Tribological Behaviour ◽  
Die Surface ◽  
Tool Surface ◽  
Strip Drawing ◽  
Aluminium Sheets ◽  
Increased Susceptibility

The increasing demands for lightweight design in the transport industry have led to an extensive use of lightweight materials such as aluminium alloys. The forming of aluminium sheets however presents significant challenges due to the low formability and the increased susceptibility to galling. The use of tailored workpieces and controlled die roughness surfaces are common strategies to improve the tribological behaviour, whilst galling is still not well understood. This work is aimed at analysing the interplay between the sheet and tool surface roughness on the friction and galling performance. Different degrees of Electro Discharge Texturing (EDT) textures were generated in AA1050 material strips, and tooling presenting different polishing degrees were prepared. Strip drawing tests were carried out to model the tribological condition and results were corroborated through cup drawing tests. A new galling severity index (GSI) is presented for a quick and quantitative determination of both galling occurrence and severity. The present study underlines the key role of die topography and the potential of die surface functionalization for galling prevention.

scholarly journals Involvement of the Inconstant Bursa of the Fifth Metatarsophalangeal Joint in Psoriatic Arthritis: A Clinical and Ultrasonographic Study

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Giovanni Ciancio ◽  
Stefania Volpinari ◽  
Maria Fotinidi ◽  
Federica Furini ◽  
Ilaria Farina ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Healthy Subjects ◽  
Statistical Significance ◽  
Metatarsophalangeal Joint ◽  
Metatarsal Bone ◽  
The Other ◽  
Control Group ◽  
Asymptomatic Patients ◽  
Seronegative Spondyloarthritis ◽  
The Difference

Objective. To evaluate the involvement of the bursa located next to the head of the 5th metatarsal bone in patients with psoriatic arthritis (PsA) in comparison with the other seronegative spondyloarthritis (SpA).Methods. All patients with PsA seen during a period of 24 months were enrolled. The control group included healthy subjects and patients with the other SpA. All subjects underwent clinical and ultrasound (US) examination of the lateral surface of the 5th metatarsal.Results. 150 PsA patients (88 M; 62 F), 172 SpA (107 M; 65 F), and 95 healthy controls (58 M; 37 F) were evaluated. Based on clinical and US evaluation, bursitis was diagnosed in 17/150 (11.3%) PsA patients but in none of the SpA (P<0.0001) and healthy (P=0.0002) controls. In detecting bursitis, US was more sensitive than clinical examination, although the difference did not reach statistical significance (P=0.09).Conclusion. The bursa of the 5th metatarsophalangeal joint appears to be involved in PsA more frequently than by chance. If confirmed by other studies, this finding could be considered as a distinctive clinical sign of PsA, useful for differential diagnosis with the other SpA. In asymptomatic patients, US proved to be more sensitive in the detection of bursitis.

Comparison of a commercially available assay system with two reference methods for the determination of plasma cholinesterase variants.

1983 ◽  
Vol 29 (10) ◽  
pp. 1746-1751 ◽  
Author(s):  
M Whittaker ◽  
J J Britten ◽  
P J Dawson
Keyword(s):  
Genetic Variants ◽  
Plasma Cholinesterase ◽  
Assay System ◽  
The Other ◽  
Reference Methods ◽  
Assay Procedure ◽  
Common Genetic Variants

Abstract For assaying plasma cholinesterase (EC 3.1.1.8) activity and phenotyping by means of dibucaine inhibition, we have compared a commercially available kit, in which butyrylthiocholine is used as substrate, with two reference methods, one using benzoylcholine and the other propionylthiocholine. With 50 different samples of three of the most common genetic variants, we could clearly differentiate the variants with benzoylcholine and dibucaine, whereas there was some overlap of the E1uE1u and E1uE1a phenotypes with the other two substrates at 30 degrees C. The phenotypes were better differentiated at 25 degrees C, and in our hands the use of butyrylthiocholine was preferable to propionylthiocholine for phenotyping with dibucaine. The affinity of the usual and atypical homozygotes for fluoride with butyrylthiocholine gave an inverted response to the affinity of these variants for the anion with benzoylcholine. We suggest that this may be explained by the role of the chromogen or its products in the assay procedure with the thiocholine substrate.

scholarly journals Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

BMJ Open ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. e032552 ◽  
Author(s):  
Bernd Schweikert ◽  
Chiara Malmberg ◽  
Mercedes Núñez ◽  
Tatiana Dilla ◽  
Christophe Sapin ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Cost Effectiveness ◽  
Maintenance Therapy ◽  
Induction Period ◽  
Severity Index ◽  
Cost Effectiveness Analysis ◽  
Severe Psoriasis ◽  
Base Case ◽  
Psoriasis Area Severity Index ◽  
Effectiveness Analysis

ObjectiveTo conduct a cost-effectiveness analysis from the perspective of the Spanish National Health System (NHS) comparing ixekizumab versus secukinumab.DesignA Markov model with a lifetime horizon and monthly cycles was developed based on the York model. Four health states were included: a biological disease-modifying antirheumatic drug (bDMARD) induction period of 12 or 16 weeks, maintenance therapy, best supportive care (BSC) and death. Treatment response was assessed based on both Psoriatic Arthritis Response Criteria (PsARC) and ≥90% improvement in the Psoriasis Area Severity Index score (PASI90). At the end of the induction period, responders transitioned to maintenance therapy. Non-responders and patients who discontinued maintenance therapy transitioned to BSC. Clinical efficacy data were derived from a network meta-analysis. Health utilities were generated by applying a regression analysis to Psoriasis Area Severity Index and Health Assessment Questionnaire‒Disability Index scores collected in the ixekizumab SPIRIT studies. Results were subject to extensive sensitivity and scenario analysis.SettingSpanish NHS.ParticipantsA hypothetical cohort of bDMARD-naïve patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis was modelled.InterventionsIxekizumab and secukinumab.ResultsIxekizumab performed favourably over secukinumab in the base-case analysis, although cost savings and quality-adjusted life-year (QALY) gains were modest. Total costs were €153 901 compared with €156 559 for secukinumab (difference −€2658). Total QALYs were 9.175 vs 9.082 (difference 0.093). Base-case results were most sensitive to the annual bDMARD discontinuation rate and the modification of PsARC and PASI90 response to ixekizumab or secukinumab.ConclusionIxekizumab provided more QALYs at a lower cost than secukinumab, with differences being on a relatively small scale. Sensitivity analysis showed that base-case results were generally robust to changes in most input parameters.Trial registration numberSPIRIT-P1: NCT01695239; Post-results, SPIRIT-P2: NCT02349295; Post-results.

scholarly journals Superiority of a vitamin B12-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis

2017 ◽  
Vol 30 (4) ◽  
pp. 439-444 ◽  
Author(s):  
Ester Del Duca ◽  
Francesca Farnetani ◽  
Nathalie De Carvalho ◽  
Ugo Bottoni ◽  
Giovanni Pellacani ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Severity Index ◽  
Vitamin B ◽  
Psoriasis Area Severity Index ◽  
Wide Range ◽  
Significant Difference ◽  
Therapy Option ◽  
The Difference ◽  
Time Point ◽  
Emollient Cream

Psoriasis is a chronic inflammatory skin disease affecting 2%–3% of the population. The wide range of drugs currently available for its treatment could be associated, in the long term, with organ toxicity and adverse events, thus, clinical monitoring throughout treatment is required. This investigator-initiated trial (IIT) evaluated the efficacy and the safety of a vitamin B12-containing ointment in comparison with glycerol-petrolatum-based emollient cream used twice a day to treat mild-to-moderate plaque psoriasis for a period over 12 weeks followed by a wash-out observation period of 4 weeks. This study was conducted as a randomized, controlled, single-blind, intra-patient left- to right-side trial comparing the efficacy and safety of vitamin B12-containing ointment (M-treatment) with a glycerol-petrolatum-based emollient cream (C-treatment). The Psoriasis Area Severity Index (PASI) was determined at baseline (T0), at time points T2 (14 days), T4 (4 weeks), T8 (8 weeks), T12 (12 weeks) and 4 weeks after the end of the wash-out period (F1). In total, 24 patients with plaque psoriasis were randomized to receive left- or right-side treatment with B12 ointment. From time point T2 to time point F1, there was a statistically significant difference in PASI reduction between M-treatment side and C-treatment side. At time point T 12, the difference between the mean reductions from baseline PASI scores by 5.92 ± 2.49 (87, 6%) in the M-treatment side versus 1.08 ± 1.02 (23, 1%) C-treatment side was statistically highly significant ( PWex < 0.001). On the contemporary panorama in the treatment of psoriasis, we conclude that vitamin B12 ointment will represent a new concrete therapy option and should be considered in the update of therapeutic algorithm for the treatment of psoriasis

Psoriatic Nail Disease: Quality of Life and Treatment

2009 ◽  
Vol 13 (5_suppl) ◽  
pp. S102-S106 ◽  
Author(s):  
Aditya K. Gupta ◽  
Elizabeth A. Cooper
Keyword(s):  
Quality Of Life ◽  
Psoriatic Arthritis ◽  
Plaque Psoriasis ◽  
Large Scale ◽  
Severity Index ◽  
Biologic Therapies ◽  
Nail Psoriasis ◽  
Psoriatic Nail Disease

Nail psoriasis is common among patients with plaque psoriasis or psoriatic arthritis and has a detrimental effect on quality of life. However, there are currently no standardized therapeutic regimens for nail psoriasis. Traditional treatments for nail psoriasis, which include topical, intralesional, and oral therapies, may be time-consuming, painful, or unsafe when administered long term. Biologic therapies have demonstrated efficacy for plaque psoriasis and psoriatic arthritis; these therapies may be particularly promising for the treatment of nail psoriasis as both groups of patients have an elevated incidence of nail dystrophy. The biologic therapies adalimumab, alefacept, efalizumab, etanercept, and infliximab have demonstrated clinically important nail psoriasis improvements using the Nail Psoriasis Severity Index, a helpful tool that, upon validation, will allow comparison across treatments and trials. Large-scale, long-term trials using standardized outcome measures are needed to further evaluate biologic therapies for the treatment of nail psoriasis.

LA RELATION CHEZ AVICENNE

2006 ◽  
Vol 16 (2) ◽  
pp. 237-286 ◽  
Author(s):  
HATEM ZGHAL
Keyword(s):  
The Other ◽  
The Subject ◽  
To Receive ◽  
Determining Factor

This study consists in a commentary on some passages from Avicenna, which deal with the category of the relative. The commentary points out the promotion of the relative to the role of an exclusive determining factor. An attempt is made here to show how Avicenna tries to detach the relative accident from its subject, in order to transform it into the exclusive determining factor of a pure thingness. The relative determination of this thingness must be able to receive specifications, which may extend as far as the infimae species. These specifications are obtained by the consideration of the other attributes of the subject of the relative attribution, which are henceforth no more than the “modes of advent” of the relation.

Sign in / Sign up

Export Citation Format

Share Document